特発性肺線維症の世界市場:薬品タイプ別(ピルフェニドン、ニンテダニブ)

Allied Market Researchが発行した調査報告書(AMR8040285)
◆英語タイトル:Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023
◆商品コード:AMR8040285
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2017年9月
◆ページ数:150
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Medical Devices & Supplies
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥558,480見積依頼/購入/質問フォーム
5 UserUSD5,910 ⇒換算¥614,640見積依頼/購入/質問フォーム
Enterprise UserUSD7,800 ⇒換算¥811,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

本資料は、特発性肺線維症の世界市場について調べ、特発性肺線維症の世界規模、市場シェア、市場動向、市場環境、薬品タイプ別(ピルフェニドン、ニンテダニブ)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・特発性肺線維症の世界市場概要
・特発性肺線維症の世界市場環境
・特発性肺線維症の世界市場動向
・特発性肺線維症の世界市場規模
・特発性肺線維症の世界市場:市場シェア
・特発性肺線維症の世界市場:薬品タイプ別(ピルフェニドン、ニンテダニブ)
・特発性肺線維症の世界市場:地域別市場規模・分析
・特発性肺線維症の北米市場規模・予測
・特発性肺線維症のアメリカ市場規模・予測
・特発性肺線維症のヨーロッパ市場規模・予測
・特発性肺線維症のアジア市場規模・予測
・特発性肺線維症の日本市場規模・予測
・特発性肺線維症の中国市場規模・予測
・関連企業情報
【レポートの概要】

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.
Recent industry trends and developments and the future opportunities are also covered.
Extensive knowledge about the key market players and their strategies is provided.
Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments

By Type of Drug

Pirfenidone
Nintedanib

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key market players

The key players operating in this market include
MediciNova, Inc.
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen, Inc.
Promedior, Inc.
Merck & Co., Inc.
Galapagos NV
Biogen
Bristol-Myers Squibb Company
Prometic Life Sciences Inc.
Cipla Inc.

【レポートの目次】

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

CHAPTER 4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PIRFENIDONE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NINTEDANIB

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. South Korea
5.4.8. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1. MEDICINOVA, INC.

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. FIBROGEN, INC.

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. PROMEDIOR, INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. GALAPAGOS NV

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. BIOGEN

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. BRISTOL-MYERS SQUIBB COMPANY

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. PROMETIC LIFE SCIENCES INC.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments

6.11. CIPLA INC.

6.11.1. Company overview
6.11.2. Operating business segments
6.11.3. Business performance
6.11.4. Key strategic moves and developments

TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 2. PIRFENIDONE MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 3. PIRFENIDONE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 4. NINTEDANIB MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 5. NINTEDANIB MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 8. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 9. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 10. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 11. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 12. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 13. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 14. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 15. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 16. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 17. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 18. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 19. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 20. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 21. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 22. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 23. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 24. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 25. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 26. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 27. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 28. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE, 2016-2023, ($MILLION)
TABLE 29. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 30. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 31. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 32. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 33. MEDICINOVA, INC.: COMPANY SNAPSHOT
TABLE 34. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 35. ROCHE: COMPANY SNAPSHOT
TABLE 36. FIBROGEN: COMPANY SNAPSHOT
TABLE 37. PROMEDIOR: COMPANY SNAPSHOT
TABLE 38. MERCK: COMPANY SNAPSHOT
TABLE 39. GALAPAGOS: COMPANY SNAPSHOT
TABLE 40. BIOGEN: COMPANY SNAPSHOT
TABLE 41. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 42. PROMETIC LIFE SCIENCES INC.: COMPANY SNAPSHOT
TABLE 43. CIPLA INC.: COMPANY SNAPSHOT

FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP INVESTMENT POCKETS
FIGURE 6. MARKET SHARE ANALYSIS, 2016
FIGURE 7. IMPACT ANALYSIS, 2016

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 特発性肺線維症の世界市場:薬品タイプ別(ピルフェニドン、ニンテダニブ)(Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023)]についてメールでお問い合わせはこちらでお願いします。